142 related articles for article (PubMed ID: 10371571)
1. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.
Levy Y; Capitant C; Houhou S; Carriere I; Viard JP; Goujard C; Gastaut JA; Oksenhendler E; Boumsell L; Gomard E; Rabian C; Weiss L; Guillet JG; Delfraissy JF; Aboulker JP; Seligmann M
Lancet; 1999 Jun; 353(9168):1923-9. PubMed ID: 10371571
[TBL] [Abstract][Full Text] [Related]
2. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
[TBL] [Abstract][Full Text] [Related]
3. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
[TBL] [Abstract][Full Text] [Related]
5. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial.
Levy Y; Durier C; Krzysiek R; Rabian C; Capitant C; Lascaux AS; Michon C; Oksenhendler E; Weiss L; Gastaut JA; Goujard C; Rouzioux C; Maral J; Delfraissy JF; Emilie D; Aboulker JP;
AIDS; 2003 Feb; 17(3):343-51. PubMed ID: 12556688
[TBL] [Abstract][Full Text] [Related]
6. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
[TBL] [Abstract][Full Text] [Related]
7. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.
Hengge UR; Goos M; Esser S; Exner V; Dötterer H; Wiehler H; Borchard C; Müller K; Beckmann A; Eppner MT; Berger A; Fiedler M
AIDS; 1998 Dec; 12(17):F225-34. PubMed ID: 9863864
[TBL] [Abstract][Full Text] [Related]
8. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
9. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection.
Simonelli C; Zanussi S; Sandri S; Comar M; Lucenti A; Talamini R; Bortolin MT; Giacca M; De Paoli P; Tirelli U
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):20-7. PubMed ID: 9928725
[TBL] [Abstract][Full Text] [Related]
10. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC
N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018
[TBL] [Abstract][Full Text] [Related]
11. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
Pakker NG; Kroon ED; Roos MT; Otto SA; Hall D; Wit FW; Hamann D; van der Ende ME; Claessen FA; Kauffmann RH; Koopmans PP; Kroon FP; ten Napel CH; Sprenger HG; Weigel HM; Montaner JS; Lange JM; Reiss P; Schellekens PT; Miedema F
AIDS; 1999 Feb; 13(2):203-12. PubMed ID: 10202826
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects.
Larsen CS; Ostergård L; Møller BK; Buhl MR
Scand J Infect Dis; 2000; 32(2):153-60. PubMed ID: 10826900
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U
AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263
[No Abstract] [Full Text] [Related]
14. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.
Katlama C; Carcelain G; Duvivier C; Chouquet C; Tubiana R; De Sa M; Zagury L; Calvez V; Autran B; Costagliola D;
AIDS; 2002 Oct; 16(15):2027-34. PubMed ID: 12370501
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with =250/microL CD4 T cells and undetectable plasma virus load.
Arnó A; Ruiz L; Juan M; Jou A; Balagué M; Zayat MK; Marfil S; Martínez-Picado J; Martínez MA; Romeu J; Pujol-Borrell R; Lane C; Clotet B
J Infect Dis; 1999 Jul; 180(1):56-60. PubMed ID: 10353861
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 therapy in patients with HIV infection.
; ; Abrams D; Lévy Y; Losso MH; Babiker A; Collins G; Cooper DA; Darbyshire J; Emery S; Fox L; Gordin F; Lane HC; Lundgren JD; Mitsuyasu R; Neaton JD; Phillips A; Routy JP; Tambussi G; Wentworth D
N Engl J Med; 2009 Oct; 361(16):1548-59. PubMed ID: 19828532
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study.
Wood R; Montoya JG; Kundu SK; Schwartz DH; Merigan TC
J Infect Dis; 1993 Mar; 167(3):519-25. PubMed ID: 8095058
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
20. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]